Octin Health Raises $2.5M Seed for Aortic Arch Surgery Device

Octin Health Closes $2.5M Seed Round

Minnesota-based medical-device startup Octin Health has raised $2.5 million in seed funding, according to company funding data dated September 20, 2026. Groove Capital participated in the round. No lead investor was disclosed.

What Octin Health Does

Octin Health is developing the Elika Device, a medical device designed to maintain blood flow to the brain and body during aortic arch surgery. The device aims to eliminate the need for deep hypothermic circulatory arrest — the 1950s-era technique of cooling the body and halting all circulation during surgery.

Deep hypothermic circulatory arrest has been a standard approach in aortic arch procedures for decades, but it carries inherent risks associated with stopping circulation and cooling the patient. Octin Health's thesis is that the Elika Device can preserve perfusion during the procedure, potentially improving outcomes and simplifying a technically demanding operation.

Founding and Team

The company was founded in 2024 by Dr. Meghana Helder, a Mayo Clinic-trained cardiovascular surgeon. That clinical background is significant in the medical-device sector, where physician-founders often bring deep procedural insight and credibility with the surgical community that adopts new technologies.

Regulatory Path

Octin Health plans to submit the Elika Device for FDA clearance in early 2027. That timeline places the company in the pre-submission phase, meaning the seed capital will likely support continued development and preparation for the regulatory process.

Recent Recognition

The company won the 2026 MN Cup grand prize, a Minnesota-based startup competition. That recognition adds visibility and validation as Octin Health moves toward its FDA submission.

Why This Round Matters

Seed funding for a medical-device company at the pre-clearance stage is typically used to advance device development, build out engineering and regulatory capabilities, and prepare for the FDA process. For Octin Health, the $2.5 million provides runway as it works toward its early-2027 submission target.

Acquisition Angle

Medical-device companies addressing well-established surgical procedures are frequent acquisition targets for larger medtech strategics. Aortic arch surgery is a specialized field, and a device that meaningfully changes the standard of care — in this case by removing the need for circulatory arrest — could attract interest from established cardiovascular device manufacturers.

Key factors that make Octin Health notable for strategic buyers and investors:

• A physician-founder with Mayo Clinic training and direct familiarity with the procedure
• A device targeting a specific, well-defined clinical problem
• A clear regulatory milestone — FDA clearance submission planned for early 2027
• External validation through the 2026 MN Cup grand prize
• Participation from Groove Capital in the seed round

For acquirers, the value inflection point will likely be tied to regulatory progress and clinical evidence. A successful FDA clearance would substantially de-risk the asset and open the door to partnership or acquisition discussions with larger cardiovascular device players.

What to Watch

• Progress toward the early-2027 FDA clearance submission
• Any additional clinical or engineering milestones for the Elika Device
• Whether Octin Health raises a follow-on round ahead of or after the regulatory submission
• Further participation from Groove Capital or new investors

Octin Health has not disclosed a lead investor for the round. The funding date is September 20, 2026.